Literature DB >> 9111295

Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 2. Conformational constraint in the "address" sequence.

S Arttamangkul1, J E Ishmael, T F Murray, D K Grandy, G E DeLander, B L Kieffer, J V Aldrich.   

Abstract

Several cyclic lactam analogues of Dyn A-(1-13)NH2 were prepared in order to reduce the conformational flexibility in different regions of the native linear peptide. Cyclo[D-Asp(i),Dap(i+3)]Dyn A-(1-13)NH2 (Dap = alpha,beta-diaminopropionic acid) analogues were designed on the basis of molecular modeling using AMBER, which suggested that this constraint may be compatible with an alpha-helix. The cyclic portion of these constrained analogues spanned from residues 3 to 9, a region proposed by Schwyzer (Biochemistry 1986, 25, 4281) to adopt a helical conformation at kappa receptor sites. Analogues containing Dab (alpha,gamma-diaminobutyric acid) or Orn in position i + 3 were also synthesized to examine the effects of larger ring size. The cyclic peptides exhibited marked differences in binding affinities for kappa, mu, and delta receptors and in opioid activity in the guinea pig ileum (GPI). Cyclo[D-Asp6,Dap9]Dyn A-(1-13)NH2 showed both high kappa receptor affinity and potent agonist activity in the GPI, while cyclo[D-Asp3,Dap6]Dyn A-(1-13)NH2 exhibited very weak binding affinity at all opioid receptors as well as very weak opioid activity in the GPI. Cyclo[D-Asp5,Dap8]Dyn A-(1-13)NH2 showed moderate binding affinity for kappa receptors and was the most kappa selective ligand in this study, but this peptide exhibited very weak agonist activity in the GPI assay. Compared to the corresponding linear peptides, all of the cyclic peptides exhibited decreased mu receptor affinity, while kappa receptor affinity was retained or improved. Therefore the corresponding linear peptides were generally mu selective while the cyclic constrained peptides demonstrated slight selectivity for kappa vs mu receptors or were nonselective. Increasing the ring size by incorporating Dab or Orn in positions 6, 8, or 9 did not significantly affect the binding affinity for the three opioid receptor types nor the opioid activity observed in the GPI. Circular dichroism spectra of the cyclo[D-Asp(i),Dap(i+3)] derivatives in 80% trifluoroethanol at 25 and 5 degrees C suggested differences in the stability of a helical structure when the constraint was incorporated near the N-terminus vs in the middle of the peptide.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9111295     DOI: 10.1021/jm960753p

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  15 in total

1.  Novel opioid cyclic tetrapeptides: Trp isomers of CJ-15,208 exhibit distinct opioid receptor agonism and short-acting κ opioid receptor antagonism.

Authors:  Nicolette C Ross; Kate J Reilley; Thomas F Murray; Jane V Aldrich; Jay P McLaughlin
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

2.  Design, synthesis, and opioid activity of arodyn analogs cyclized by ring-closing metathesis involving Tyr(allyl).

Authors:  Wei-Jie Fang; Thomas F Murray; Jane V Aldrich
Journal:  Bioorg Med Chem       Date:  2017-11-21       Impact factor: 3.641

3.  Macrocyclic peptides decrease c-Myc protein levels and reduce prostate cancer cell growth.

Authors:  Archana Mukhopadhyay; Laura E Hanold; Hamsa Thayele Purayil; Solomon A Gisemba; Sanjeewa N Senadheera; Jane V Aldrich
Journal:  Cancer Biol Ther       Date:  2017-07-10       Impact factor: 4.742

4.  Unexpected opioid activity profiles of analogues of the novel peptide kappa opioid receptor ligand CJ-15,208.

Authors:  Jane V Aldrich; Santosh S Kulkarni; Sanjeewa N Senadheera; Nicolette C Ross; Kate J Reilley; Shainnel O Eans; Michelle L Ganno; Thomas F Murray; Jay P McLaughlin
Journal:  ChemMedChem       Date:  2011-07-14       Impact factor: 3.466

5.  Deletion of Ac-NMePhe(1) from [NMePhe(1) ]arodyn under acidic conditions, part 2: effects of substitutions on pharmacological activity.

Authors:  Wei-Jie Fang; Marco A Bennett; Thomas F Murray; Jane V Aldrich
Journal:  Biopolymers       Date:  2011       Impact factor: 2.505

6.  Alanine scan of the opioid peptide dynorphin B amide.

Authors:  Anand A Joshi; Thomas F Murray; Jane V Aldrich
Journal:  Biopolymers       Date:  2017-09       Impact factor: 2.505

7.  Dual labeled peptides as tools to study receptors: nanomolar affinity derivatives of TIPP (Tyr-Tic-Phe-Phe) containing an affinity label and biotin as probes of delta opioid receptors.

Authors:  Jane V Aldrich; Vivek Kumar; Thomas F Murray; Wei Guang; Jia Bei Wang
Journal:  Bioconjug Chem       Date:  2009-02       Impact factor: 4.774

8.  Alanine analogues of [D-Trp]CJ-15,208: novel opioid activity profiles and prevention of drug- and stress-induced reinstatement of cocaine-seeking behaviour.

Authors:  J V Aldrich; S N Senadheera; N C Ross; K A Reilley; M L Ganno; S E Eans; T F Murray; J P McLaughlin
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

9.  Discovery of dermorphin-based affinity labels with subnanomolar affinity for mu opioid receptors.

Authors:  Bhaswati Sinha; Zhengyu Cao; Thomas F Murray; Jane V Aldrich
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

10.  Design, synthesis, and pharmacological activities of dynorphin A analogues cyclized by ring-closing metathesis.

Authors:  Wei-Jie Fang; Yanjun Cui; Thomas F Murray; Jane V Aldrich
Journal:  J Med Chem       Date:  2009-09-24       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.